An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D

Grants and Contracts Details

StatusActive
Effective start/end date4/5/223/13/23

Funding

  • IO Biotech ApS: $19,431.00